As PD-L1 expression by cancer cells and regulatory immune cells is expected to repress anti-tumor immune responses, translational studies have searched for the role of PD-1/PD-L1 pathway in the prognosis of rectal cancer patients (Table 3). This evidence concerns the gene PDCD1 and neoplasm.